Carter Cliff is CEO of Papillon Therapeutics. He has raised over $230 Million as co-founder and executive of biotechnology companies developing disease-modifying genetic medicines, including Opsis Therapeutics and Kenai Therapeutics. Opsis entered a Strategic R&D Alliance with BlueRock Therapeutics (a Bayer AG company), who provided a $70 Million up-front commitment to option three programs. Kenai raised an $83 Million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures, and The Column Group, with participation from Euclidean Capital and Saisei Ventures.